# VANI — Vivani Medical Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** VANI  
**Sources:** 21  
**Published:** 2026-10-27  
**Canonical:** https://app.k3vl4r.com/research/deep-research-vani-vivani-medical-inc-catalysts-narrative-risks-9629

---

## Vivani Medical (VANI) — Research Snapshot as of 2026-10-27

**Company profile:** Vivani Medical is a clinical-stage biopharmaceutical company based in Alameda, California, trading on Nasdaq under ticker VANI. It develops miniature, subdermal drug implants using its proprietary NanoPortal™ platform, targeting chronic-disease management via once- or twice-yearly drug delivery. Its lead candidate is NPM-139 (a semaglutide/GLP-1 implant for chronic weight management), with NPM-133 (semaglutide for type 2 diabetes) in the pipeline, plus the neurostimulation subsidiary Cortigent (brain-computer interface / artificial vision). [[3]](https://www.nasdaq.com/press-release/vivani-medical-reports-second-quarter-2026-financial-results-and-provides-business), [[22]](https://vivani.com/vivani/), [[24]](https://vivani.com/)

**Market snapshot:** Stock ~$1.14, market cap ~$102.8M, shares outstanding ~90.2M, beta 3.30 (high volatility), short interest ~0.99% of float, insider ownership ~53.3%, institutional ~6.8%. [[14]](https://www.marketbeat.com/stocks/NASDAQ/VANI/), [[16]](https://finance.yahoo.com/quote/VANI/), [[18]](https://stockanalysis.com/stocks/vani/)

---

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-vani-vivani-medical-inc-catalysts-narrative-risks-9629 (free to sign up)._